Skip to main content

Phensuximide Disease Interactions

There are 4 disease interactions with phensuximide:

Major

Succinimides (applies to phensuximide) blood dyscrasias

Major Potential Hazard, Low plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts

Hematologic toxicities, some with fatal outcome, have been associated with the use of succinimide anticonvulsants. Leukopenia, agranulocytosis, aplastic anemia, thrombocytopenia, pancytopenia, and eosinophilia have been reported. Therapy with succinimide anticonvulsants should be administered cautiously in patients with preexisting blood dyscrasias and/or bone marrow suppression. Complete blood counts, including platelets, should be performed prior to initiating therapy and periodically during therapy. Marked depression of blood counts may be indication for withdrawal of succinimide therapy.

References

  1. "Product Information. Celontin Kapseals (methsuximide)." Parke-Davis, Morris Plains, NJ.
  2. American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association; (1994):
  3. Massey GV, Dunn NL, Heckel JL, Myer EC, Russell EC "Aplastic anemia following therapy for absence seizures with ethosuximide." Pediatr Neurol 11 (1994): 59-61
  4. "Product Information. Milontin (phensuximide)." Parke-Davis, Morris Plains, NJ.
  5. Seip M "Aplastic anemia during ethosuximide medication. Treatment with bolus- methylprednisolone." Acta Paediatr Scand 72 (1983): 927-9
  6. "Product Information. Zarontin (ethosuximide)." Parke-Davis, Morris Plains, NJ.
View all 6 references
Major

Succinimides (applies to phensuximide) renal/liver disease

Major Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Succinimide anticonvulsants have produced morphological and functional changes in the liver of animals. In humans, abnormalities in liver and renal function studies have been reported. Therapy with succinimide anticonvulsants should be administered with extreme caution in patients with known hepatic or renal diseases. Periodic urinalysis and liver function tests are recommended for all patients treated with these drugs.

References

  1. "Product Information. Zarontin (ethosuximide)." Parke-Davis, Morris Plains, NJ.
  2. Korinthenberg R, Wehrle L, Zimmerhackl LB "Renal tubular dysfunction following treatment with anti-epileptic drugs." Eur J Pediatr 153 (1994): 855-8
  3. "Product Information. Milontin (phensuximide)." Parke-Davis, Morris Plains, NJ.
  4. Coulter DL "Ethosuximide-induced liver dysfunction." Arch Neurol 40 (1983): 393-4
  5. "Product Information. Celontin Kapseals (methsuximide)." Parke-Davis, Morris Plains, NJ.
  6. Silverman SH, Gribetz D, Rausen AR "Nephrotic syndrome associated with ethosuccimide." Am J Dis Child 132 (1978): 99
View all 6 references
Major

Succinimides (applies to phensuximide) SLE

Major Potential Hazard, Moderate plausibility. Applicable conditions: Lupus Erythematosus

Cases of systemic lupus erythematosus (SLE) have been reported in association with the use of succinimide anticonvulsants, primarily ethosuximide. Some of the patients recovered promptly following discontinuation of the drug, while others continued to have active disease long after. Therapy with succinimide anticonvulsants should be administered cautiously in patients with a history of SLE.

References

  1. Teoh PC, Chan HL "Lupus-scleroderma syndrome induced by ethosuximide." Arch Dis Child 50 (1975): 658-61
  2. Alter BP "Systemic lupus erythematosus and ethosuccimide." J Pediatr 77 (1970): 1093-5
  3. Singsen BH, Fishman L, Hanson V "Antinuclear antibodies and lupus-like syndromes in children receiving anticonvulsants." Pediatrics 57 (1976): 529-34
  4. "Product Information. Zarontin (ethosuximide)." Parke-Davis, Morris Plains, NJ.
  5. "Product Information. Milontin (phensuximide)." Parke-Davis, Morris Plains, NJ.
  6. Dabbous IA, Idriss HM "Occurrence of systemic lupus erythematosus in association with ethosuccimide therapy. Case report." J Pediatr 76 (1970): 617-20
  7. Beernink DH, Miller JJ 3d "Anticonvulsant-induced antinuclear antibodies and lupus-like disease in children." J Pediatr 82 (1973): 113-7
  8. Livingston S, Rodriguez H, Greene CA, Pauli LL "Systemic lupus erythematosus. Occurrence in association with ethosuximide therapy." JAMA 203 (1968): 731-2
  9. "Product Information. Celontin Kapseals (methsuximide)." Parke-Davis, Morris Plains, NJ.
View all 9 references
Moderate

Antiepileptics (applies to phensuximide) suicidal tendency

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Depression, Psychosis

Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs across multiple indications in either monotherapy or adjunctive therapy for a median treatment duration of 12 weeks (up to a maximum of 24 weeks) showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo. The estimated rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% for 16,029 placebo-treated patients, representing an increase of approximately one case for every 530 patients treated. There were four suicides in AED-treated patients and none in placebo-treated patients, although the number is too small to establish any causal relationship. The increased risk of suicidal thoughts or behavior was observed as early as one week after starting AEDs and persisted for the duration of treatment assessed. The risk did not vary substantially by age (5 to 100 years) in the clinical trials analyzed. Therapy with AEDs should be administered cautiously in patients with depression or other psychiatric disorders. The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior. For clinically significant or persistent symptoms, a dosage reduction or treatment withdrawal should be considered. If patients have symptoms of suicidal ideation or behavior, treatment should be discontinued.

Phensuximide drug interactions

There are 224 drug interactions with phensuximide

Phensuximide alcohol/food interactions

There is 1 alcohol/food interaction with phensuximide

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.